Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients

Hemodialysis Clinical Trial

Official title:

Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00885300
• Other study ID #: 3705
• Status: Completed
• Phase: N/A
• First received: April 20, 2009
• Last updated: April 20, 2009
• Start date: January 2008
• Est. completion date: September 2008

Study information

• Verified date: April 2009
• Source: Shiraz University of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: Iran: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate whether cloxacillin lock is effective in prevention of double lumen infection.

Description:

Double lumen infection is one of the causes of morbidity and mortality in hemodialysis patients. Many strategies used to prevent it and one of them is antibiotic lock. Thus we select chronic hemodialysis patients and divided them into 2 groups. One group received cloxacillin and heparin as catheter lock and the second group received only heparin lock.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: September 2008
• Est. primary completion date: July 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• hemodialysis for 3 months

• at least 2 time dialysis/week

Exclusion Criteria:

• active infection

• acute renal failure

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Double Lumen Infection
• Hemodialysis
• Infection

Intervention

Drug:
• cloxacillin
cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
• heparin
heparin 1000iu/ml as catheter lock at the end of hemodialysis

Locations

Country	Name	City	State
Iran, Islamic Republic of	Shiraz University Hemodialysis Center	Shiraz	Fars

Sponsors (1)

Lead Sponsor	Collaborator
Shiraz University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

References & Publications (1)

Unver S, Atasoyu EM, Evrenkaya TR, Ardic N, Ozyurt M. Risk factors for the infections caused by temporary double-lumen hemodialysis catheters. Arch Med Res. 2006 Apr;37(3):348-52. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	catheter infection		6 months	Yes

External Links

•   Link